entertainment -WSS

entertainment

author：explore 2025-10-01 18:34:32 - browse：18

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Chemotherapy before breast cancer surgery might fuel metastasis

WSS

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

AltruBio raises $225 million to develop ulcerative colitis drug

BIO to announce reorganization, senior leaders expected to depart

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Here's how to stay safe from wildfire smoke amid reduced air quality

focus

entertainment

focus

Jerome Adams on the need for new antivirals for Covid

Can gargling with Listerine treat gonorrhea of the mouth?

Medical records are filled with copy

Tuskegee Airman Raymond Cassagnol dies at 102

Medical leaders decry Supreme Court decision on affirmative action

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Hepatitis C has a cure — but many Americans still lack access to it

Why do we get seasonal allergies?

entertainment

Warren pushes Witty on UnitedHealth's control over physicians

Ukrainian soldiers say they owe lives to US

BIO to announce reorganization, senior leaders expected to depart

Empower primary care with adequate payments and technology

The strange history of BMI, the body mass index

Medical experts exlpore how to eliminate bias in clinical algorithms

explore

knowledge

focus

focus